4 Investor presentation First nine months of 2022 Strategic Aspirations 2025 | High Purpose and sustainability (ESG) Progress towards zero environmental impact • Carbon emissions decreased by 18% vs 9M 2019 Adding value to society • Positive EMA opinion on human insulin with more flexible storage options • 35.7 million people treated with NN products (net increase of 1.8 million vs end of September 2021) Being recognised as a sustainable employer • Share of women in VP+ positions increased to 38% from 36% in 9M 2021 Diabetes value market share increased by 1.7%-points to 31.6% 1 Obesity care sales of DKK 11.4 billion (+75% at CER) Rare disease sales of DKK 15.7 billion (+2% at CER) Commercial execution 1 MAT (Moving annual total) value market share 9M: First nine months; EMA: European Medicines Agency; VP: Vice president; QD: Once-daily; QW: Once-weekly; CER: Constant exch Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth
Download PDF file